The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Huntington's disease: a clinical review
Open accessAbstract
Huntington's disease (HD) is a fully penetrant neurodegenerative disease caused by a dominantly inherited CAG trinucleotide repeat expansion in the huntingtin gene on chromosome 4. In Western populations HD has a prevalence of 10.6–13.7 individuals per 100 000. It is characterized by cognitive, motor and psychiatric disturbance. At the cellular level mutant huntingtin results in neuronal dysfunction and death through a number of mechanisms, including disruption of proteostasis, transcription and mitochondrial function and direct toxicity of the mutant protein. Early macroscopic changes are seen in the striatum with involvement of the cortex as the disease progresses. There are currently no disease modifying treatments; therefore supportive and symptomatic management is the mainstay of treatment. In recent years there have been significant advances in understanding both the cellular pathology and the macroscopic structural brain changes that occur as the disease progresses. In the last decade there has been a large growth in potential therapeutic targets and clinical trials. Perhaps the most promising of these are the emerging therapies aimed at lowering levels of mutant huntingtin. Antisense oligonucleotide therapy is one such approach with clinical trials currently under way. This may bring us one step closer to treating and potentially preventing this devastating condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Unexpected mutations after CRISPR–Cas9 editing in vivo
Schaefer, K. A., Wu, W.-H., Colgan, D. F., Tsang, S. H., Bassuk, A. G., & Mahajan, V. B. (2017) · Nature Methods · doi:10.1038/nmeth.4293 · Cited by 286
RetractedMACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Self-citationBates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Self-citationArgonaute proteins: key players in RNA silencing
Hutvagner, G., & Simard, M. J. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2321 · Cited by 1,359
G. Vonsattel, J. P., & DiFiglia, M. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199805000-00001 · Cited by 1,306
Huntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016
Self-citationTabrizi, S. J., Langbehn, D. R., Leavitt, B. R., Roos, R. A., Durr, A., Craufurd, D., Kennard, C., Hicks, S. L., Fox, N. C., Scahill, R. I., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70170-x · Cited by 984
Self-citationTabrizi, S. J., Scahill, R. I., Owen, G., Durr, A., Leavitt, B. R., Roos, R. A., Borowsky, B., Landwehrmeyer, B., Frost, C., Johnson, H., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70088-7 · Cited by 846
Self-citationKordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease
Lee, J.-M., Wheeler, V. C., Chao, M. J., Vonsattel, J. P. G., Pinto, R. M., Lucente, D., Abu-Elneel, K., Ramos, E. M., Mysore, J. S., Gillis, T., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.003 · Cited by 655
Tabrizi, S. J., Scahill, R. I., Durr, A., Roos, R. A., Leavitt, B. R., Jones, R., Landwehrmeyer, G. B., Fox, N. C., Johnson, H., Hicks, S. L., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70276-3 · Cited by 606
Self-citationTabrizi, S. J., Reilmann, R., Roos, R. A., Durr, A., Leavitt, B., Owen, G., Jones, R., Johnson, H., Craufurd, D., Hicks, S. L., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70263-0 · Cited by 547
Self-citationRubinsztein, D. C., Leggo, J., Coles, R., Almqvist, E., Biancalana, V., Cassiman, J. J., Chotai, K. A., Connarty, M., Crauford, D., Curtis, A., et al. (1996) · PubMed Central · Cited by 525
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Naryshkin, N. A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K. K. Y., Karp, G. M., Qi, H., Woll, M. G., et al. (2014) · Science · doi:10.1126/science.1250127 · Cited by 524
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Huntington Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000198586.85250.13 · Cited by 471
Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm
Telenius, H., Kremer, B., Goldberg, Y. P., Theilmann, J., Andrew, S. E., Zeisler, J., Adam, S., Greenberg, C., Ives, E. J., Clarke, L. A., et al. (1994) · Nature Genetics · doi:10.1038/ng0494-409 · Cited by 439
Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease
Borovecki, F., Lovrecic, L., Zhou, J., Jeong, H., Then, F., Rosas, H. D., Hersch, S. M., Hogarth, P., Bouzou, B., Jensen, R. V., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504921102 · Cited by 414
Huntington Study Group, Frank, S., Testa, C. M., Stamler, D., Kayson, E., Davis, C., Edmondson, M. C., Kinel, S., Leavitt, B., Oakes, D., et al. (2016) · JAMA · doi:10.1001/jama.2016.8655 · Cited by 403
CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease
Yang, S., Chang, R., Yang, H., Zhao, T., Hong, Y., Kong, H. E., Sun, X., Qin, Z., Jin, P., Li, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92087 · Cited by 399
Behavioral changes in Huntington Disease.
Craufurd, D., Thompson, J. C., & Snowden, J. S. (2001) · PubMed · Cited by 397
Byrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30124-2 · Cited by 364
Self-citationRAN Translation in Huntington Disease
Bañez-Coronel, M., Ayhan, F., Tarabochia, A. D., Zu, T., Perez, B. A., Tusi, S. K., Pletnikova, O., Borchelt, D. R., Ross, C. A., Margolis, R. L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.10.038 · Cited by 354
Moss, D. J. H., Pardiñas, A. F., Langbehn, D., Lo, K., Leavitt, B. R., Roos, R., Durr, A., Mead, S., Coleman, A., Santos, R. D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30161-8 · Cited by 312
Self-citationNeuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY)
van Duijn, E., Craufurd, D., Hubers, A. A. M., Giltay, E. J., Bonelli, R., Rickards, H., Anderson, K. E., van Walsem, M. R., van der Mast, R. C., Orth, M., et al. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307343 · Cited by 299
Therapies targeting DNA and RNA in Huntington's disease
Wild, E. J., & Tabrizi, S. J. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30280-6 · Cited by 298
Self-citationPermanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9
Shin, J. W., Kim, K.-H., Chao, M. J., Atwal, R. S., Gillis, T., MacDonald, M. E., Gusella, J. F., & Lee, J.-M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw286 · Cited by 276
Wild, E. J., Boggio, R., Langbehn, D., Robertson, N., Haider, S., Miller, J. R. C., Zetterberg, H., Leavitt, B. R., Kuhn, R., Tabrizi, S. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80743 · Cited by 268
Self-citationPallos, J., Bodai, L., Lukacsovich, T., Purcell, J. M., Steffan, J. S., Thompson, L. M., & Marsh, J. L. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn273 · Cited by 265
Recommendations for the predictive genetic test in Huntington's disease
MacLeod, R., Tibben, A., Frontali, M., Evers‐Kiebooms, G., Jones, A., Martinez‐Descales, A., Roos, R., & Editorial Committee and Working Group ‘Genetic Testing Counselling’ of the European Huntington Disease Network (2013) · Clinical Genetics · doi:10.1111/j.1399-0004.2012.01900.x · Cited by 237
Dalrymple, A., Wild, E. J., Joubert, R., Sathasivam, K., Björkqvist, M., Petersén, Å., Jackson, G. S., Isaacs, J. D., Kristiansen, M., Bates, G. P., et al. (2007) · Journal of Proteome Research · doi:10.1021/pr0700753 · Cited by 228
Self-citationPaulsen, J. S., Long, J. D., Ross, C. A., Harrington, D. L., Erwin, C. J., Williams, J. K., Westervelt, H. J., Johnson, H. J., Aylward, E. H., Zhang, Y., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70238-8 · Cited by 227
Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY
Orth, M., Handley, O. J., Schwenke, C., Dunnett, S. B., Craufurd, D., Ho, A. K., Wild, E., Tabrizi, S. J., & Landwehrmeyer, G. B. (2011) · PLoS Currents · doi:10.1371/currents.rrn1184 · Cited by 208
Self-citationC9orf72 expansions are the most common genetic cause of Huntington disease phenocopies
Hensman Moss, D. J., Poulter, M., Beck, J., Hehir, J., Polke, J. M., Campbell, T., Adamson, G., Mudanohwo, E., McColgan, P., Haworth, A., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000061 · Cited by 203 · cited 1×
“The most common of these in European populations are C9orf72 [37] and spinocerebellar ataxia (SCA) 17 [36].”
BackgroundSelf-citationde Yebenes, J. G., Landwehrmeyer, B., Squitieri, F., Reilmann, R., Rosser, A., Barker, R. A., Saft, C., Magnet, M. K., Sword, A., Rembratt, Å., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70233-2 · Cited by 171
The cognitive burden in Huntington's disease: Pathology, phenotype, and mechanisms of compensation
Papoutsi, M., Labuschagne, I., Tabrizi, S. J., & Stout, J. C. (2014) · Movement Disorders · doi:10.1002/mds.25864 · Cited by 165
Self-citationGenetic modifiers of Huntington's disease
Gusella, J. F., MacDonald, M. E., & Lee, J. (2014) · Movement Disorders · doi:10.1002/mds.26001 · Cited by 158
Huntington’s Disease—Update on Treatments
Wyant, K. J., Ridder, A. J., & Dayalu, P. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0739-9 · Cited by 157
Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease
Coppen, E. M., & Roos, R. A. C. (2016) · Drugs · doi:10.1007/s40265-016-0670-4 · Cited by 153
Dumas, E. M., van den Bogaard, S. J. A., Ruber, M. E., Reilmann, R., Stout, J. C., Craufurd, D., Hicks, S. L., Kennard, C., Tabrizi, S. J., van Buchem, M. A., et al. (2011) · Human Brain Mapping · doi:10.1002/hbm.21205 · Cited by 147
Self-citationCompensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study
Klöppel, S., Gregory, S., Scheller, E., Minkova, L., Razi, A., Dürr, A., Roos, R. A. C., Leavitt, B. R., Papoutsi, M., Landwehrmeyer, G. B., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.08.002 · Cited by 146
Self-citationThe association of CAG repeat length with clinical progression in Huntington disease
Rosenblatt, A., Liang, K.-Y., Zhou, H., Abbott, M. H., Gourley, L. M., Margolis, R. L., Brandt, J., & Ross, C. A. (2006) · Neurology · doi:10.1212/01.wnl.0000204230.16619.d9 · Cited by 146
Stout, J. C., Jones, R., Labuschagne, I., O’Regan, A., Say, M. J., Dumas, E. M., Queller, S., Justo, D., Santos, R. D., Coleman, A., et al. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301940 · Cited by 146
Self-citation† (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70262-5 · Cited by 144
Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression
Weiss, A., Träger, U., Wild, E. J., Grueninger, S., Farmer, R. E., Landles, C., Scahill, R. I., Lahiri, N., Salman, H., Macdonald, D., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64565 · Cited by 143
Self-citationCorticostriatal synaptic adaptations in Huntington's disease
Plotkin, J. L., & Surmeier, D. J. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.01.020 · Cited by 136
A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease
The Huntington Study Group HART Investigators (2013) · Movement Disorders · doi:10.1002/mds.25362 · Cited by 130
Age, CAG repeat length, and clinical progression in Huntington's disease
Rosenblatt, A., Kumar, B. V., Mo, A., Welsh, C. S., Margolis, R. L., & Ross, C. A. (2011) · Movement Disorders · doi:10.1002/mds.24024 · Cited by 126
Network topology and functional connectivity disturbances precede the onset of Huntington’s disease
Harrington, D. L., Rubinov, M., Durgerian, S., Mourany, L., Reece, C., Koenig, K. A., Bullmore, E. T., Long, J. D., Paulsen, J. S., for the PREDICT-HD investigators of the Huntington Study Group, et al. (2015) · Brain · doi:10.1093/brain/awv145 · Cited by 125
Natural History of Huntington Disease
Dorsey, E. R. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4408 · Cited by 124
Altered PDE10A expression detectable early before symptomatic onset in Huntington’s disease
Niccolini, F., Salman, H., Marques, T. R., Muhlert, N., Tziortzi, A. C., Searle, G. E., Natesan, S., Piccini, P. P., Kapur, S., Rabiner, E. A., et al. (2015) · Brain · doi:10.1093/brain/awv214 · Cited by 120
Self-citationHuntington's disease phenocopies are clinically and genetically heterogeneous
Wild, E. J., Mudanohwo, E. E., Sweeney, M. G., Schneider, S. A., Beck, J. A., Bhatia, K. P., Rossor, M. N., Davis, M. B., & Tabrizi, S. J. (2008) · Movement Disorders · doi:10.1002/mds.21915 · Cited by 116
Self-citationBeaumont, V., Zhong, S., Lin, H., Xu, W., Bradaïa, A., Steidl, E., Gleyzes, M., Wadel, K., Buisson, B., Padovan‐Neto, F. E., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.10.064 · Cited by 115
Changes in mental state and behaviour in Huntington's disease
Eddy, C. M., Parkinson, E. G., & Rickards, H. E. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30144-4 · Cited by 111
Dorsey, E. R., & the Huntington Study Group COHORT Investigators (2012) · PLoS ONE · doi:10.1371/journal.pone.0029522 · Cited by 104
McColgan, P., Seunarine, K. K., Razi, A., Cole, J. H., Gregory, S., Dürr, A., Roos, R. A. C., Stout, J. C., Landwehrmeyer, G. B., Scahill, R. I., et al. (2015) · Brain · doi:10.1093/brain/awv259 · Cited by 98
Self-citationRunne, H., Régulier, E., Kuhn, A., Zala, D., Gökçe, Ö., Perrin, V., Sick, B., Aebischer, P., Déglon, N., & Luthi‐Carter, R. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3044-08.2008 · Cited by 96
Huntington's disease phenocopy syndromes
Wild, E. J., & Tabrizi, S. J. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3282f12074 · Cited by 96
Self-citationCerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
Rodrigues, F. B., Byrne, L. M., McColgan, P., Robertson, N., Tabrizi, S. J., Leavitt, B. R., Zetterberg, H., & Wild, E. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13719 · Cited by 82
Self-citationTravessa, A., Rodrigues, F. B., Mestre, T., & Ferreira, J. J. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-170245 · Cited by 82
Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington's disease
Rodrigues, F. B., Byrne, L. M., McColgan, P., Robertson, N., Tabrizi, S. J., Zetterberg, H., & Wild, E. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163479 · Cited by 79
Self-citationCholinesterase inhibitors for rarer dementias associated with neurological conditions
Li, Y., Hai, S., Zhou, Y., & Dong, B. R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009444.pub3 · Cited by 78
Interrater agreement in the assessment of motor manifestations of Huntington's disease
Hogarth, P., Kayson, E., Kieburtz, K. D., Marder, K. S., Oakes, D., Rosas, H. D., Shoulson, I., Wexler, N. S., Young, A. B., Zhao, H., et al. (2004) · Movement Disorders · doi:10.1002/mds.20332 · Cited by 78
Cerebrospinal Fluid Biomarkers for Huntington’s Disease
Byrne, L. M., & Wild, E. J. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160196 · Cited by 78
Deyts, C., Galan-Rodriguez, B., Martin, E., Bouveyron, N., Roze, E., Charvin, D., Caboche, J., & Bétuing, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008287 · Cited by 67
Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?
Rodrigues, F. B., Duarte, G. S., Costa, J. N., Ferreira, J. J., & Wild, E. J. (2017) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12483 · Cited by 66
Results of the citalopram to enhance cognition in Huntington disease trial
Beglinger, L. J., Adams, W. H., Langbehn, D., Fiedorowicz, J. G., Jorge, R., Biglan, K., Caviness, J., Olson, B., Robinson, R. G., Kieburtz, K., et al. (2014) · Movement Disorders · doi:10.1002/mds.25750 · Cited by 65
Agustín‐Pavón, C., Mielcarek, M., Garriga-Canut, M., & Isalan, M. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0128-x · Cited by 65
The Huntington Study Group PHAROS Investigators* (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.991 · Cited by 62
Vijayvargia, R., Epand, R., Leitner, A., Jung, T., Shin, B., Jung, R., Lloret, A., Atwal, R. S., Lee, H., Lee, J.-M., et al. (2016) · eLife · doi:10.7554/elife.11184 · Cited by 61
Diagnostic genetic testing for Huntington's disease
Craufurd, D., MacLeod, R., Frontali, M., Quarrell, O., Bijlsma, E. K., Davis, M. B., Hjermind, L. E., Lahiri, N., Mandich, P., Martinez, A., et al. (2014) · Practical Neurology · doi:10.1136/practneurol-2013-000790 · Cited by 59
Sampaio, C., Borowsky, B., & Reilmann, R. (2014) · Movement Disorders · doi:10.1002/mds.26021 · Cited by 51
Vijayvargia, R., Epand, R. F., Leitner, A., Jung, T., Shin, B., Jung, R., Lloret, A., Atwal, R. S., Lee, H., Lee, J., et al. (2016) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-b-000114979 · Cited by 48
van der Meer, L. B., van Duijn, E., Wolterbeek, R., & Tibben, A. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01778.x · Cited by 45
Hersch, S. M., Jones, R., Koroshetz, W. J., & Quaid, K. A. (1994) · Neurology · doi:10.1212/wnl.44.8.1369 · Cited by 44
Gregory, S., Cole, J. H., Farmer, R. E., Rees, E. M., Roos, R. A. C., Sprengelmeyer, R., Dürr, A., Landwehrmeyer, G. B., Zhang, H. G., Scahill, R. I., et al. (2015) · Journal of Huntington s Disease · doi:10.3233/jhd-150173 · Cited by 37
Self-citationReilmann, R., Squitieri, F., Priller, J., et al. (2014) · Neurology · doi:10.1212/wnl.82.10_supplement.s47.004 · Cited by 17
Cited by
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., Li, C., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,052
Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases
Kapellos, T. S., Bonaguro, L., Gemünd, I., Reusch, N., Saglam, A., Hinkley, E. R., & Schultze, J. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02035 · Cited by 890
Structural variant calling: the long and the short of it
Mahmoud, M., Gobet, N., Cruz-Dávalos, D. I., Mounier, N., Dessimoz, C., & Sedlazeck, F. J. (2019) · Genome Biology · doi:10.1186/s13059-019-1828-7 · Cited by 725
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Self-citation
Metadata
- Authors
- McColgan, P., & Tabrizi, S. J.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2017-09-22
- Volume
- 25
- Issue
- 1
- Pages
- 24-34
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2745482791
- Cited by
- 1,089
- References
- 78
- FWCI
- 24.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.